• Guideline Summary
  • NGC:010253
  • 2010 Jul (revised 2013 Apr)

Epithelial ovarian, fallopian tube, and primary peritoneal cancer.

  • Guideline Summary
  • NGC:009549
  • 2012 Dec

Colposcopic management of abnormal cervical cytology and histology.

  • Guideline Summary
  • NGC:010883
  • 2015 Mar

Somatostatin analogues for the management of neuroendocrine tumours.

  • Guideline Summary
  • NGC:009388
  • 2012 Feb

Penile cancer.

  • Guideline Summary
  • NGC:010426
  • 2006 Mar (revised 2014 May)

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

  • Guideline Summary
  • NGC:010264
  • 2012 Mar (revised 2013 Feb)

Preoperative and pretreatment investigations for malignant melanoma.

  • Guideline Summary
  • NGC:010367
  • 2014

The role of postoperative radiation therapy for endometrial cancer: an ASTRO evidence-based guideline.

  • Guideline Summary
  • NGC:010540
  • 2013 Aug

EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer.

  • Guideline Summary
  • NGC:010283
  • 2005 Sep (revised 2013 Dec)

Management of abnormal cervical cancer screening test results and cervical cancer precursors.

  • Guideline Summary
  • NGC:009492
  • 2012 Nov 28

Best evidence statement (BESt). Psycho-social interventions for primary caregivers of newly diagnosed pediatric oncology patients.

  • Guideline Summary
  • NGC:010035
  • 2013 Apr 18

Screening high-risk populations for lung cancer.

  • Guideline Summary
  • NGC:010022
  • 1998 Oct (revised 2013 Sep)

Treatment of primary breast cancer. A national clinical guideline.

  • Guideline Summary
  • NGC:010011
  • 2013 Aug

Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy.

  • Guideline Summary
  • NGC:008801
  • 2004 Jan (revised 2011 Mar)

Pregnancy and breast cancer.

  • Guideline Summary
  • NGC:009671
  • 2005 (revised 2012)

ACR Appropriateness Criteria® prostate cancer—pretreatment detection, staging and surveillance.

  • Guideline Summary
  • NGC:009073
  • 2003 Oct (revised 2012 Apr)

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70).